Publications by authors named "Tara Maier"
Article Synopsis
- Immune-related cutaneous adverse events (ircAEs) affect over 50% of patients on checkpoint inhibitors, yet their mechanisms remain unclear.
- A study examined 200 patients (139 with ircAEs and 61 controls) to identify clinical presentations and cytokine responses, leading to the discovery of eight different ircAE phenotypes, such as pruritus and eczema, each involving immune cell infiltration.
- Analysis showed unique cytokine profiles related to specific phenotypes, revealing potential treatment strategies that could involve targeted therapies or corticosteroids for effective management of these adverse events.
IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events.
Pharmaceuticals (Basel)
November 2023
: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype. We report the use of ustekinumab as a therapeutic option.
View Article and Find Full Text PDF